Kinetics of Circulating Cell-free DNA for Biomedical Applications: Critical Appraisal of the Literature

Overview

Journal Future Sci OA

Specialty Biotechnology

Date 2018 Apr 24

PMID 29682327

Citations 63

Authors

Sonia Khier

Laura Lohan

Affiliations

Soon will be listed here.

Abstract

Circulating cell-free DNA is considered as one of the major breakthroughs in the field of innovative diagnosis, used as a liquid biopsy. The kinetic parameters of a biomarker are mandatory to assess its usefulness as a diagnostic tool. Obtaining precise mathematical values for the kinetic parameters (e.g., half-life) is then crucial because it could be used for therapeutic monitoring as a prognostic factor. However, little is known about the intrinsic properties of circulating cell-free DNA, more especially, its kinetic properties within the organism. We summarized the basic principles that may affect the kinetics of circulating cell-free DNA within the organism in the light of biological and clinical evidence. We also meta-analyzed the reported data in the literature and the methodologies that have been used to study the kinetic parameters of human circulating cell-free DNA .

Citing Articles

Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma.

Martinez-Vila C, Teixido C, Aya F, Martin R, Gonzalez-Navarro E, Alos L Int J Mol Sci. 2025; 26(2).

PMID: 39859576 PMC: 11766255. DOI: 10.3390/ijms26020861.

Evaluation of a biomarker for amyotrophic lateral sclerosis derived from a hypomethylated DNA signature of human motor neurons.

Harvey C, Nowak A, Zhang S, Moll T, Weimer A, Barcons A BMC Med Genomics. 2025; 18(1):10.

PMID: 39810183 PMC: 11734586. DOI: 10.1186/s12920-025-02084-w.

Melanoma's New Frontier: Exploring the Latest Advances in Blood-Based Biomarkers for Melanoma.

Prkacin I, Mokos M, Ferara N, Situm M Cancers (Basel). 2025; 16(24.

PMID: 39766118 PMC: 11727356. DOI: 10.3390/cancers16244219.

Patient-Specific Circulating Tumor DNA for Monitoring Response to Menin Inhibitor Treatment in Preclinical Models of Infant Leukemia.

Doculara L, Evans K, Gooding J, Bayat N, Lock R Cancers (Basel). 2024; 16(23).

PMID: 39682177 PMC: 11640178. DOI: 10.3390/cancers16233990.

Evaluation of a biomarker for amyotrophic lateral sclerosis derived from a hypomethylated DNA signature of human motor neurons.

Harvey C, Nowak A, Zhang S, Moll T, Weimer A, Barcons A Res Sq. 2024; .

PMID: 39649175 PMC: 11623773. DOI: 10.21203/rs.3.rs-5397445/v1.

References

Salvi S, Martignano F, Molinari C, Gurioli G, Calistri D, De Giorgi U . The potential use of urine cell free DNA as a marker for cancer. Expert Rev Mol Diagn. 2016; 16(12):1283-1290. DOI: 10.1080/14737159.2016.1254551. View

Almufti R, Wilbaux M, Oza A, Henin E, Freyer G, Tod M . A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment. Ann Oncol. 2013; 25(1):41-56. DOI: 10.1093/annonc/mdt382. View

Zhang W, Wu J, Qiao B, Xu W, Xiong S . Amelioration of lupus nephritis by serum amyloid P component gene therapy with distinct mechanisms varied from different stage of the disease. PLoS One. 2011; 6(7):e22659. PMC: 3143173. DOI: 10.1371/journal.pone.0022659. View

Emlen W, Mannik M . Kinetics and mechanisms for removal of circulating single-stranded DNA in mice. J Exp Med. 1978; 147(3):684-99. PMC: 2184197. DOI: 10.1084/jem.147.3.684. View

Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View

Laktionov P, Tamkovich S, Rykova E, Bryzgunova O, Starikov A, Kuznetsova N . Cell-surface-bound nucleic acids: Free and cell-surface-bound nucleic acids in blood of healthy donors and breast cancer patients. Ann N Y Acad Sci. 2004; 1022:221-7. DOI: 10.1196/annals.1318.034. View

Diehl F, Schmidt K, Choti M, Romans K, Goodman S, Li M . Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008; 14(9):985-90. PMC: 2820391. DOI: 10.1038/nm.1789. View

Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K . Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004; 10(18 Pt 1):5981-7. DOI: 10.1158/1078-0432.CCR-04-0625. View

Rumore P, Muralidhar B, Lin M, Lai C, Steinman C . Haemodialysis as a model for studying endogenous plasma DNA: oligonucleosome-like structure and clearance. Clin Exp Immunol. 1992; 90(1):56-62. PMC: 1554541. DOI: 10.1111/j.1365-2249.1992.tb05831.x. View

10.

Kragh-Hansen U, Chuang V, Otagiri M . Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull. 2002; 25(6):695-704. DOI: 10.1248/bpb.25.695. View

11.

Gold B, Cankovic M, Furtado L, Meier F, Gocke C . Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. J Mol Diagn. 2015; 17(3):209-24. PMC: 4411248. DOI: 10.1016/j.jmoldx.2015.02.001. View

12.

Gahan P, Chayen J . Cytoplasmic deoxyribonucleic acid. Int Rev Cytol. 1965; 18:223-47. DOI: 10.1016/s0074-7696(08)60555-0. View

13.

Stroun M, Anker P . Prehistory of the notion of circulating nucleic acids in plasma/serum (CNAPS): birth of a hypothesis. Ann N Y Acad Sci. 2006; 1075:10-20. DOI: 10.1196/annals.1368.002. View

14.

Fleischhacker M, Schmidt B . Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta. 2006; 1775(1):181-232. DOI: 10.1016/j.bbcan.2006.10.001. View

15.

Mould D, Upton R . Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 2013; 1:e6. PMC: 3606044. DOI: 10.1038/psp.2012.4. View

16.

Ette E, Williams P . Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother. 2004; 38(10):1702-6. DOI: 10.1345/aph.1D374. View

17.

Vlassov V, Laktionov P, Rykova E . Extracellular nucleic acids. Bioessays. 2007; 29(7):654-67. DOI: 10.1002/bies.20604. View

18.

Seredkina N, Zykova S, Rekvig O . Progression of murine lupus nephritis is linked to acquired renal Dnase1 deficiency and not to up-regulated apoptosis. Am J Pathol. 2009; 175(1):97-106. PMC: 2708798. DOI: 10.2353/ajpath.2009.080943. View

19.

Mould D, Upton R . Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013; 2:e38. PMC: 3636497. DOI: 10.1038/psp.2013.14. View

20.

Dewez B, Lans M, Allaeys V, Karaoglou A, Taper H, Roberfroid M . Serum alkaline deoxyribonuclease activity, a sensitive marker for the therapeutic monitoring of cancer patients: methodological aspects. Eur J Clin Chem Clin Biochem. 1993; 31(11):793-7. View